biOasis Technologies Ord Shs V.BTI.H

RE:RE:BTI seems to be relatively unknown even at this point.

[JDavenport]

It's not how big the BNN number is, it's what viewers do after the viewing.

True accomplishment, how important it is, and how widely it's carried in the media are the criteria for attracting investors and increasing the share price. The value of the coverage and the resulting positive affect on share price could perhaps be in an order of magnitude like this:

1. Bioasis clinical success.
2. Partner clinical success.
3. Licensee clinical success.
4. Significant partnership deal with a Bioasis pipeline drug.
5. Significant licensing deal with a Bioasis drug or program (like Chiesi deal)
6. Selling of a Bioasis pipeline drug to a pharma. (This could be higher depending on pharma and price.)
7. Bioasis announcement of clinical trial start.
8. Partner announcement of clinical trial start.
9. Licensee announcement of clinical trial start.
10. Bioasis achieving IND status on a drug.
11. Partner achieving IND status on a drug.
12. Licensee achieving IND status on a drug.
13. Developmental milestone payments to Bioasis.
14. Regulatory milestone payments to Bioasis.
15. Licensee release of preclinical study information.*
16. Partner release of preclinical study information.*
17. Bioasis release of preclinical study information. (like progranulin, IL-1Ra)*
18. Free media coverage, voluntarily done by media but without announcement of accomplishment.
19. Executive, medical and scientific hirings. (Could have greater impact if the person is newsworthy)
20. Financial reports and MD&A.
21. Financings,
22. Paid media coverage with announcement of accomplishment. (Stock promotion)
23. Paid media coverage without announcement of accomplishment. (Stock promotion)

* Items 15, 16 and 17: With respect to the release of preclinical study information, Licensee, partner and Bioasis are ordered in reverse compared to other news detailed higher in the list. This is because partners and licensees are likely to attract more attention to Bioasis with preclinical studies than Bioasis can with its own release.

I left out commercial milestone and royalty payments because they are likely many years away.

This is a sort of quick and dirty list. I'm interested in comments, including things I may have forgotten.

jd